MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK) and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire EyeBio. Read more.